Literature DB >> 33253499

Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.

Medha Barbhaiya1, Stephane Zuily2, Yasaman Ahmadzadeh3, Mary-Carmen Amigo4, Tadej Avcin5, Maria Laura Bertolaccini6, D Ware Branch7, Guilherme de Jesus8, Katrien M J Devreese9, Camille Frances10, David Garcia11, Francis Guillemin12, Steven R Levine13, Roger A Levy14, Michael D Lockshin1, Thomas L Ortel15, Surya V Seshan16, Maria Tektonidou17, Denis Wahl2, Rohan Willis18, Ray Naden, Karen Costenbader19, Doruk Erkan1.   

Abstract

OBJECTIVE: An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence- and consensus-based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains.
METHODS: During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains.
RESULTS: Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification.
CONCLUSION: Using data- and consensus-driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real-world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.
© 2020, American College of Rheumatology.

Entities:  

Mesh:

Year:  2021        PMID: 33253499      PMCID: PMC8966711          DOI: 10.1002/acr.24520

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  49 in total

1.  Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology.

Authors:  José A Martínez-Flores; Manuel Serrano; Javier Alfaro; Sergio Mora; Estela Paz-Artal; José M Morales; Antonio Serrano
Journal:  Anal Chem       Date:  2013-11-26       Impact factor: 6.986

Review 2.  16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome.

Authors:  Guilherme R de Jesús; Ashley E Benson; Cecilia B Chighizola; Savino Sciascia; David W Branch
Journal:  Lupus       Date:  2020-09-03       Impact factor: 2.911

Review 3.  Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.

Authors:  Sara K Tedeschi; Sindhu R Johnson; Dimitrios Boumpas; David Daikh; Thomas Dörner; David Jayne; Diane Kamen; Kirsten Lerstrøm; Marta Mosca; Rosalind Ramsey-Goldman; Corine Sinnette; David Wofsy; Josef S Smolen; Raymond P Naden; Martin Aringer; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

Review 4.  Distinctions between diagnostic and classification criteria?

Authors:  Rohit Aggarwal; Sarah Ringold; Dinesh Khanna; Tuhina Neogi; Sindhu R Johnson; Amy Miller; Hermine I Brunner; Rikke Ogawa; David Felson; Alexis Ogdie; Daniel Aletaha; Brian M Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

5.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

6.  Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

Authors:  Yu Pei Chock; Thomas Moulinet; Virginie Dufrost; Doruk Erkan; Denis Wahl; Stéphane Zuily
Journal:  Autoimmun Rev       Date:  2019-09-11       Impact factor: 9.754

Review 7.  14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

Authors:  Maria Laura Bertolaccini; Olga Amengual; Laura Andreoli; Tatsuya Atsumi; Cecilia B Chighizola; Ricardo Forastiero; Philip de Groot; Gabriella Lakos; Marc Lambert; Pierluigi Meroni; Thomas L Ortel; Michelle Petri; Anisur Rahman; Robert Roubey; Savino Sciascia; Melissa Snyder; Anne E Tebo; Angela Tincani; Rohan Willis
Journal:  Autoimmun Rev       Date:  2014-05-10       Impact factor: 9.754

8.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).

Authors:  Stavros V Konstantinides; Guy Meyer; Cecilia Becattini; Héctor Bueno; Geert-Jan Geersing; Veli-Pekka Harjola; Menno V Huisman; Marc Humbert; Catriona Sian Jennings; David Jiménez; Nils Kucher; Irene Marthe Lang; Mareike Lankeit; Roberto Lorusso; Lucia Mazzolai; Nicolas Meneveau; Fionnuala Ní Áinle; Paolo Prandoni; Piotr Pruszczyk; Marc Righini; Adam Torbicki; Eric Van Belle; José Luis Zamorano
Journal:  Eur Heart J       Date:  2020-01-21       Impact factor: 35.855

9.  Influence of anticardiolipin and anti-β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification.

Authors:  Laura Vanoverschelde; Hilde Kelchtermans; Jacek Musial; Bas de Laat; Katrien M J Devreese
Journal:  Res Pract Thromb Haemost       Date:  2019-05-26

Review 10.  Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome.

Authors:  Sarah Abramson Stoots; Lindsay Lief; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2019-09-06       Impact factor: 4.592

View more
  6 in total

Review 1.  Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.

Authors:  Arne Vandevelde; Katrien M J Devreese
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

2.  The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study.

Authors:  Gilberto Pires da Rosa; Bernardo Sousa-Pinto; Ester Ferreira; Olga Araújo; Giuseppe Barilaro; Paulo Bettencourt; Ricard Cervera; Gerard Espinosa
Journal:  Arthritis Res Ther       Date:  2022-01-03       Impact factor: 5.156

Review 3.  Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.

Authors:  Aline Garcia Islabão; Vitor Cavalcanti Trindade; Licia Maria Henrique da Mota; Danieli Castro Oliveira Andrade; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-12-13       Impact factor: 3.022

4.  Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.

Authors:  Jacqueline A Madison; Kelsey Gockman; Claire Hoy; Ajay Tambralli; Yu Zuo; Jason S Knight
Journal:  Pediatr Rheumatol Online J       Date:  2022-02-23       Impact factor: 3.054

Review 5.  Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence.

Authors:  Alfonso-Ragnar Torres-Jimenez; Virginia Ramirez-Nova; Adriana Ivonne Cespedes-Cruz; Berenice Sanchez-Jara; Alejandra Velazquez-Cruz; Vilma Carolina Bekker-Méndez; Francisco Xavier Guerra-Castillo
Journal:  Pediatr Rheumatol Online J       Date:  2022-02-14       Impact factor: 3.054

6.  Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series.

Authors:  Shawn A Mahmud; Danielle R Bullock; Colleen K Correll; Patricia M Hobday; Mona M Riskalla; Richard K Vehe; Bryce A Binstadt
Journal:  Pediatr Rheumatol Online J       Date:  2022-08-20       Impact factor: 3.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.